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al therapies. These mechanisms may lead to branched sub-
clonal evolution from a common progenitor clone, resulting 
in spatial variation between different tumor sites, disease 
progression, and treatment resistance. This review address-
es tumor heterogeneity in lymphomas from a pathologist’s 
viewpoint. The relationship between morphologic, immun-
ophenotypic, and genetic heterogeneity is exemplified in 
different lymphoma entities and reviewed in the context of 
high-grade transformation and transdifferentiation. In addi-
tion, factors driving heterogeneity, as well as clinical and 
therapeutic implications of lymphoma heterogeneity, will 
be discussed.  © 2017 S. Karger AG, Basel 
 Introduction 
 Tumor heterogeneity is a phenomenon that has long 
been recognized by pathologists, cancer researchers, 
and medical oncologists. Tumor heterogeneity can con-
ceptually be divided into intertumoral and intratumoral 
heterogeneity. Intertumoral heterogeneity describes the 
variability in morphology, immunophenotypes, genetic 
aberrations, epigenetic events, therapy responses, and 
clinical outcomes of distinct tumor entities in different 
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 Abstract 
 The facts that cancer represents tissues consisting of hetero-
geneous neoplastic, as well as reactive, cell populations and 
that cancers of the same histotype may show profound dif-
ferences in clinical behavior have long been recognized. 
With the advent of new technologies and the demands of 
precision medicine, the investigation of tumor heterogene-
ity has gained much interest. An understanding of intertu-
moral heterogeneity in patients with the same disease entity 
is necessary to optimally guide personalized treatment. In 
addition, increasing evidence indicates that different tumor 
areas or primary tumors and metastases in an individual pa-
tient can show significant intratumoral heterogeneity on dif-
ferent levels. This phenomenon can be driven by genomic 
instability, epigenetic events, the tumor microenvironment, 
and stochastic variations in cellular function and antitumor-
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patients. In contrast, intratumoral heterogeneity desig-
nates the variability of individual tumor cells and tumor 
subclones within the complex and dynamic ecosystem 
of a given neoplasm in a single patient  [1–6] . Intratu-
moral heterogeneity can be influenced by the interac-
tions of cancer cells with other cancer cells (clonal coop-
erativity/competition)  [7] and of cancer cells with cells 
and structures of the tumor microenvironment (i.e., im-
mune cells, vasculature, cancer-associated fibroblasts, 
and extracellular matrix), by tissue oxygenation, pH, 
and nutrient availability, and by stochastic variation in 
cellular function. Intratumoral heterogeneity also de-
scribes the divergence between primary tumor and met-
astatic sites as well as temporal heterogeneity depending 
on the point of analysis of primary versus recurrent tu-
mors  [1–3, 6] .
 The concepts on the origins of intratumoral heteroge-
neity were extensively discussed already more than 30 
years ago  [8] . At that time, evidence for intratumoral het-
erogeneity was mostly obtained in cell lines or animal ex-
periments and was only indirectly observed in human 
cancers. In recent years, however, the field of tumor het-
erogeneity has witnessed unprecedented advances due to 
new genetic and computational technologies that enable 
massive parallel DNA sequencing to study cancer ge-
nomes at a large scale. These efforts have revealed an in-
triguing inter- and intratumoral genetic heterogeneity in 
a wide variety of malignancies including lymphomas and 
they have had a considerable impact on cancer diagnos-
tics and treatment  [1–3, 9] . In addition, genetic heteroge-
neity has been shown to influence disease progression 
and outcomes as well as the response to therapy  [10–12] . 
Besides genetic heterogeneity, processes that are not 
readily analyzable by genome or exome sequencing, such 
as DNA methylation, histone modification, micro-RNA 
and noncoding RNA, and tumor cell phenotype, as well 
as the interactions between tumor cells and the microen-
vironment, may play important roles in functional het-
erogeneity  [3] . Further layers of complexity are intro-
duced by the hierarchical organization of some tumors 
into a bulk of malignant cells and so-called cancer stem 
cells that have the ability to self-renew and thereby pose 
a reservoir for long-term maintenance of malignant 
growth  [13] .
 In this review, we will focus on tumor heterogeneity in 
lymphomas, emphasizing morphologic, immunopheno-
typic, and genetic heterogeneity; intratumoral heteroge-
neity and subclonal evolution; and transformation and 
transdifferentiation, as well as clinical and therapeutic as-
pects. Further investigation into lymphoma heterogene-
ity will allow a more precise diagnosis and treatment of 
individual patients’ diseases and it will pave the way to-
wards highly personalized lymphoma management.
 Malignant Lymphomas Mirror the Complexity of the 
Immune System 
 In the 2016 updated 4th edition of the World Health 
Organization (WHO) classification of tumors of hema-
topoietic and lymphoid tissues, more than 90 different 
categories of B- and T-cell lymphomas are distinguished 
 [14, 15] . This complex classification, which tries to group 
lymphomas according to their putative cell of origin, as 
well as their clinical and pathological features, reflects 
our deepening understanding of the immune system, 
with different lymphocyte subsets undergoing complex 
maturation steps and each step potentially having malig-
nant counterparts. The precise classification of a pa-
tient’s lymphoma is crucial to predict the clinical course 
(from indolent to aggressive) and to guide the choice of 
treatment regimen, from “watch and wait” to multimod-
al (radio-, immuno-, chemo-) therapy  [16–19] . Histo-
morphologic and cytologic analyses of the growth pat-
tern, tissue architecture, cell size, nuclear features, and 
reactive microenvironment of a given tumor by micros-
copy of stained tissue slides are still the most important 
tools for establishing a diagnosis of lymphoma. Ancillary 
studies, such as immunohistochemistry and sometimes 
molecular testing, are required to confirm the diagnosis 
and to further classify the entity for prognostic and pre-
dictive purposes.
 Intratumoral Heterogeneity in Lymphoma 
 Lymphomas in individual patients can exhibit differ-
ent types of intratumoral heterogeneity ( Table  1 ), and 
this phenomenon is often of prognostic and predictive 
importance. In a proportion of patients, 2 distinct lym-
phoma entities as defined by the WHO criteria can be 
diagnosed either at different time points of the disease or 
simultaneously at the first diagnosis in the same organ or 
in different organs, such as lymph nodes (LN) and bone 
marrow (BM). Irrespectively of the setting, it is of major 
importance to investigate – usually by studying clonal im-
munoglobulin or T-cell receptor rearrangements – 
whether intratumoral heterogeneity is the result of evolu-
tion of the neoplastic clone or indicates the presence of a 
second, clonally unrelated neoplasm  [20] .
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 The most common example of intratumoral heteroge-
neity is the evolution of a low-grade lymphoma into a 
high-grade lymphoma during the disease course, known 
as lymphoma transformation ( Fig.  1 ). Transformation, 
considered to represent clonal evolution, is usually asso-
ciated with clinical disease progression and an adverse 
outcome  [21] . In chronic lymphocytic leukemia/small 
lymphocytic lymphoma (CLL/SLL), high-grade transfor-
mation into diffuse large B-cell lymphoma (DLBCL) is 
known as Richter’s syndrome (RS) and occurs in up to 
10% of patients, with an estimated transformation rate of 
0.5–1% per year  [22] . Of note, 10–20% of DLBCL in pa-
tients with CLL/SLL are clonally unrelated to the CLL/
SLL. These patients show a superior prognosis compared 
to true, clonally related RS  [23–25] . Rarely, CLL/SLL, as 
well as other B-cell non-Hodgkin lymphomas (B-NHL), 
may transform into classical Hodgkin lymphoma (HL). 
For the cases of classical HL, which are frequently Ep-
stein-Barr virus positive, determination of clonal rela-
tionship is very difficult for technical reasons, but several 
studies using single-cell analysis have demonstrated that 
classical HL in the setting of CLL/SLL and other indolent 
B-NHL may be both clonally related and clonally unre-
lated ( Fig. 2 )  [26, 27] . The 10-year risk of transformation 
in follicular lymphoma (FL), the most frequent low-grade 
B-NHL, ranges between 15 and 20%, with an annual 
transformation rate of about 2–3%  [28] . Marginal zone 
lymphoma transforms into high-grade lymphoma in 10–
14% of patients over time, although the true incidence 
rates of transformation are poorly documented  [21] .
 Secondly and less frequently, patients are simultane-
ously diagnosed with a low-grade and a high-grade lym-
phoma at different anatomical sites. This spatial form of 
intratumoral heterogeneity, known as discordant in-
volvement, occurs in 5–7% of patients according to recent 
studies  [29–31] and most often presents as DLBCL in an 
LN with discordant low-grade lymphoma infiltration in 
the BM  [20] . In patients with a low-grade and a high-
grade component at different sites, it is of major impor-
tance to investigate the clonal relationship between the 2 
components. Kremer et al.  [32] demonstrated that in 
DLBCL patients a significant fraction of cases with dis-
cordant BM involvement harbors clonally unrelated sec-
ondary low-grade B-cell neoplasms such as monoclonal 
 Table 1. Definitions
Composite lymphoma Example of intratumoral heterogeneity; a lymphoma that consists of at least 2 different entities that occur 
simultaneously in the same organ (“collision tumor”)
Concordant involvement BM (or other organ) infiltration by the same lymphoma entity
Discordant lymphoma Example of spatial heterogeneity; occurrence of 2 histologically distinct lymphoma types in 2 different 
anatomical locations; most often observed as high-grade lymphoma in a lymph node with discordant BM 
involvement by a low-grade lymphoma
Gray zone lymphomas High-grade lymphomas that display overlapping or borderline morphologic, immunophenotypic, and 
biological features between different lymphoma entities and therefore cannot be unequivocally catego-
rized [36, 37]
Relapse Recurrence of a morphologically identical lymphoma after therapy; most often clonally related, some-
times clonally unrelated [61]; thought to arise from a common lymphoma progenitor through linear or 
branched evolution in clonally related cases
Transdifferentiation Example of intratumoral heterogeneity; presence of a myeloid neoplasm (most often histiocytic/dendritic 
cell sarcoma) in a lymphoma patient, hypothesized to derive from the lymphoma clone or a CPC based 
on the demonstration of identical gene rearrangements, mutations, or chromosomal translocations in 
both tumor components
Transformation Example of temporal heterogeneity; progression of a low-grade lymphoma into a high-grade lymphoma 
(usually DLBCL; less commonly lymphoblastic lymphoma, Burkitt lymphoma, PBL, BCL-U, or CHL) 
during the disease course; known as Richter’s syndrome in CLL; transformation is associated with treat-
ment resistance, clinical disease progression, and increased disease-specific mortality; cooccurrence of 
transformed lymphoma is not considered composite lymphoma
BM, bone marrow; CPC, common progenitor cell/clone; DLBCL, diffuse large B-cell lymphoma; PBL, plasmablastic lymphoma; 
BCL-U, B-cell lymphoma, unclassified; CHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia. 
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B-cell lymphocytosis or CLL/SLL. Furthermore, a third 
corresponded to reactive lymphoid infiltrates. These facts 
may contribute to the superior survival of patients with 
discordant as compared to concordant BM involvement 
in DLBCL.
 Thirdly and least frequently, 2 different, usually clon-
ally unrelated lymphoma entities coincide within the 
same organ, presenting as a “collision tumor” known as a 
composite lymphoma. Composite lymphomas, intrigu-
ing examples of intratumoral heterogeneity, consist of
either 2 separate B-NHL ( Fig. 3 ) or a combination of B-
NHL and HL and occur in only 1–4% of lymphoma pa-
tients  [33, 34] . Rarely, classical HL collides with nodular 
lymphocyte-predominant HL  [35] . In composite lym-
phomas, tumor borders can be clearly defined, or tumor 
cells can be partly intermixed. Composite lymphomas 
should not be confounded with the so-called gray zone 
lymphomas, which are high-grade lymphomas that dis-
play overlapping or borderline morphologic, immuno-
phenotypic, and biological features between different 
lymphoma entities and therefore cannot be unequivocal-
ly categorized  [36, 37] .
 In addition, some low-grade lymphoma subtypes show 
a topographically defined morphologic and immunophe-
notypic intratumoral heterogeneity. For example, tumor 
cells in the proliferation centers of CLL/SLL are of a larg-
er size, exhibit an increased proliferation rate as analyzed 
by Ki-67 immunohistochemistry, and upregulate several 
antigens. In FL, tumor cells outside of the neoplastic fol-
licles often downregulate CD10 and BCL6. Phenotypic 
and sometimes morphologic heterogeneity is also ob-
served in different tumor compartments, e.g., between 
BM and LN or LN and peripheral blood  [38–42] . Further 
aspects of morphologic heterogeneity can be found in 
lymphomas that display maturation towards plasma cells, 
such as lymphoplasmacytic lymphoma. Lymphoplasma-
cytic lymphoma can demonstrate a high intertumoral 
and intratumoral heterogeneity in terms of plasma cell 
maturation, with some patients showing nearly no matu-
ration (only small lymphocytic cells) and other patients 
showing a high degree of maturation towards plasma cells 
 [43] . Importantly, after treatment with the anti-CD20 
monoclonal antibody rituximab, the loss of the lymphoid 
tumor component can be so dramatic that a misdiagnosis 
of plasma cell neoplasm might occur  [44, 45] .
 Genetic Intratumoral Heterogeneity, Clonal 
Evolution, and Transformation 
 Recent seminal studies addressing intratumoral genet-
ic heterogeneity and mechanisms of transformation in 
low-grade lymphomas have revealed highly interesting 
and important results that may change the clinical prac-
tice in the near future.
 CLL/SLL is an incurable neoplasm consisting of ma-
ture, small B cells that grow diffusely and express surface 
CD20, CD23, and CD5 and nuclear LEF1. Despite its ap-
parently homogeneous appearance and phenotype, which 
is stable among patients, CLL/SLL is clinically a highly 
heterogeneous disease that rapidly progresses in some pa-
tients while being indolent without indication for therapy 
for decades in others  [46] . This heterogeneity of CLL is 
based on a variety of clinical, phenotypic, and genetic pa-
rameters, which have led to the development of advanced 
biological prognostic scores  [47] . However, intratumoral 
heterogeneity in CLL adds another layer of complexity, 
and recent seminal work by Landau et al.  [12] has shed 
light on the underlying mechanisms. Studying 149 CLL/
SLL patients by whole-exome sequencing, they found 
that driver mutations in CLL/SLL can be divided into pre-
dominantly clonal (e.g.,  MYD88 , trisomy 12, and 
del[13q]), clonal and subclonal (e.g., del[11q], del[17p], 
and  SF3B1 ), or predominantly subclonal (e.g.,  TP53 , 
 ATM , and  CDH2 ) ( Fig. 1 )  [12] . When analyzing patients 
at different time points, they found that 10 of 12 patients 
receiving chemotherapy underwent clonal evolution 
originating from subclones with driver mutations that ex-
panded over time. In contrast, this phenomenon was only 
observed in 1 of 6 patients without treatment. They hy-
pothesized that chemotherapy leads to 2 different scenar-
ios in CLL/SLL depending on the presence or absence of 
subclonal driver mutations. If subclonal driver mutations 
are absent, chemotherapy leads to a balanced reduction 
of all malignant clones (clonal equilibrium). In contrast, 
the presence of aggressive subclones harboring driver 
mutations (which may be “controlled” by clonal competi-
tion in untreated patients) may be unmasked and selected 
 Fig. 1. Types and genetic mechanisms of transformation. Com-
mon low-grade lymphomas and their transformed counterparts 
are depicted. Percentages indicate the frequency of the type of 
transformation, according to Agbay et al.  [21] , Parikh et al. [22] , 
and Montoto and Fitzgibbon [28] . CLL/SLL, chronic lymphocytic 
leukemia/small lymphocytic lymphoma; FL, follicular lymphoma; 
MZL, marginal zone lymphoma; LPL, lymphoplasmacytic lym-
phoma; DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin lym-
phoma; PBL, plasmablastic lymphoma; BCL-U, B-cell lymphoma, 
unclassified; B-ALL, B-cell acute lymphoblastic leukemia; BL, 
Burkitt lymphoma. 
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a b c
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j k l
 Fig. 2. Nodular sclerosis classical Hodgkin lymphoma transforma-
tion of chronic lymphocytic leukemia/small lymphocytic lympho-
ma (CLL/SLL). The clonal relationship was not tested in this case. 
 a Scanning magnification shows an enlarged lymph node subdi-
vided into large nodules by broad fibrous septa. Some darker, dif-
fuse areas and lighter nodules are seen (Giemsa stain).  b Cytolog-
ically, at the border of the darker areas with lighter nodules, there 
is an admixture of small, round CLL/SLL lymphocytes with large 
Hodgkin and Reed-Sternberg cells (Giemsa stain).  c Immunohis-
tochemically,  CD20 is positive in the CLL/SLL area (left) and 
shows the typical negativity in the Hodgkin and Reed-Sternberg 
cells (right).  d PAX5 is strongly nuclear positive in the CLL/SLL 
cells and has less staining intensity in the Hodgkin and Reed-
Sternberg cells, consistent with shutdown of the B-cell gene ex-
pression programs in these cells.  e Staining for CD5 shows positiv-
ity in the CLL/SLL cells (left) and an abundant infiltrate of reactive 
T lymphocytes (CD3, not shown) intermixed with the Hodgkin 
and Reed-Sternberg cells (right).  f CD23 marks the CLL/SLL cells. 
CD15 ( g ) and CD30 ( h ) are strongly positive in the Hodgkin and 
Reed-Sternberg cells. OCT2 ( i ) and BOB1 ( j ) show nuclear positiv-
ity in the CLL/SLL cells and are negative in the Hodgkin and Reed-
Sternberg cells. LMP1 ( k ) and Epstein-Barr virus ( l ) mRNA in situ 
hybridization (EBER) are positive in the Hodgkin and Reed-Stern-
berg cells, consistent with Epstein-Barr virus infection. Magnifica-
tions: ×12.5 (scale bar, 1,000 μm) ( a ) and ×200 ( b–l ) (scale bars, 50 
μm). 
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for by chemotherapy, resulting in clonal outgrowth and 
disease progression  [12] . These findings were confirmed 
and extended in a more recent study by the same group 
that included a total of 538 CLL/SLL patients of whom 
278 were prospectively recruited  [48] . Importantly, some 
of the subclonal driver mutations described by Landau et 
al. [48] ( TP53  loss or del[17p], mutations in  NOTCH1 or 
 SF3B1 ) are implicated in the pathogenesis of RS, along 
with additional genetic events ( MYC  amplification, 
 CDKN2A/B  loss, and tri[12])  [49, 50] . Based on their 
findings that TP53 and/or CDKN2A/B inactivation were 
mutually exclusive with tri(12), Chigrinova et al.  [49]  
proposed that RS may evolve via 2 main genetic pathways, 
i.e., (1)  TP53 inactivation,  MYC activation, and 
 CDKN2A/B loss and (2) tri(12) followed by  NOTCH1 
mutation ( Fig.  1 ) These findings were independently 
confirmed by Fabbri et al.  [50] , who proposed a linear 
evolution model for CLL/SLL transformation into RS and 
demonstrated that the genetic landscape in RS-DLBCL is 
substantially different from that of de novo DLBCL. This 
provides an explanation for the different disease biology, 
the higher aggressiveness, and the much poorer outcome 
of RS-DLBCL compared to de novo DLBCL  [23–25] .
 Like CLL/SLL, FL is an incurable malignancy that 
most often presents as a low-grade tumor (grade 1–2) 
consisting of small neoplastic B cells with a follicular 
growth pattern. FL harbors an inherent risk of high-grade 
transformation with an annual incidence of 2–3%. In 
contrast to CLL/SLL, which is believed to evolve linearly, 
the current hypothesis for transformed FL (tFL) is deriva-
tion from a long-lived common progenitor cell/clone 
(CPC). Okosun et al. [51] sequenced 10 FL-tFL sample 
pairs and identified 2 distinct patterns of evolution, which 
they coined “rich” and “sparse” CPC. In 8 patients under-
going evolution along the “rich” CPC pathway, FL and 
tFL samples showed a high clonal semblance, and CPC 
harbored many mutations previously reported in DLB-
CL, such as in histone modifiers ( KMT2D ,  CREBBP , 
 EP300 ,  EZH2 , and  MEF2B ), immune genes ( B2M ,  CD58 , 
and TNFRSF14 ), JAK-STAT signaling ( SOCS1 and 
STAT6 ), and B-cell receptor-signaling genes ( BCL10 , 
 CARD11 , and CD79B ). Conversely, in 2 patients, only 4 
nonsynonymous mutations were shared by the FL and 
tFL samples (“sparse” CPC). Importantly, the FL and tFL 
clones in these 2 cases independently acquired different 
mutations in  KMT2D ,  TNFRSF14 , and  CREBBP , indicat-
ing that these genes play a very important role in FL lym-
phomagenesis and transformation. Furthermore, by per-
forming deep sequencing of 28 selected genes in an exten-
sion cohort, those authors could demonstrate 
a b
c d
e f
g h
 Fig. 3. Example of a composite lymphoma consisting of chronic 
lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) 
admixed with follicular lymphoma (FL).  a The H&E stain shows a 
lymphatic infiltrate that has a partly diffuse and partly nodular 
growth pattern with germinal center-like structures. Cytologically, 
the cells in the diffuse areas are small, round lymphocytes with 
little cytoplasm and dense nuclear chromatin, corresponding to 
CLL/SLL. In contrast, the cells in the nodules are medium sized 
centrocytes with angular nuclei, rather open chromatin, and ample 
cytoplasm with some larger, interspersed centroblasts, corre-
sponding to FL.  b CD20 staining shows diffuse positivity in all cells 
with strong staining intensity in the FL nodules and a weaker in-
tensity in the diffuse CLL/SLL areas.  c CD10 is positive in the nod-
ular areas.  d CD23 stains the diffuse areas and marks some follicu-
lar dendritic cells within the nodules.  e CD5 is weakly positive in 
the diffuse areas and strongly stains the T lymphocytes (CD3, not 
shown).  f BCL6 is positive in the nodules.  g BCL2 shows a pattern 
similar to CD20 with 2 staining intensities.  h The proliferation rate 
(Ki-67) is low in the diffuse areas ( ∼ 5%) and higher in the nodules 
( ∼ 30%). All magnifications: ×200 (scale bars, 50 μm). 
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intratumoral heterogeneity in FL in analogy to CLL/SLL. 
Clonal mutations were mostly observed in early event 
genes such as  KMT2D ,  CREBBP ,  EZH2 ,  STAT6 , and  TN-
FRSF14 , whereas subclonal mutations were observed in 
genes that were associated with transformation, like 
 MYD88 , EBF1 , and  TNFAIP3  [51] . In line with these find-
ings, a divergent pattern of evolution from an ancestor 
CPC was observed in 10 of 12 FL-tFL sample pairs studied 
by Pasqualucci et al.  [52] . Linear evolution from a minor 
subclone that harbored tFL-specific mutations and was 
already present in the diagnostic FL sample was demon-
strated in 2 patients. Importantly, this study confirmed 
and extended the findings of Okosun et al.  [51] regarding 
important genes involved in FL pathogenesis and trans-
formation ( KMT2D ,  CREBBP ,  EZH2 ,  FAS ,  BCL2 ,  TP53 , 
 MYC ,  CDKN2A/B ,  B2M , and  PIM1 ). Furthermore, these 
analyses revealed a marked genomic instability in tFL 
compared to FL and other lymphoid neoplasms  [52] . In 
analogy to the subclonal heterogeneity of CLL/SLL  [12] , 
Green et al.  [53] found that the majority of mutations in 
their 8 FL samples corresponded to minor subclonal mu-
tations that were heterozygous, with the exception of ho-
mozygous  CREBBP and  KMT2D mutations that were 
most likely clonal. Studying 2 samples with matched re-
lapsed FL, those authors proposed an elegant genetic evo-
lution model for (nontransformed) FL that is based on 
founder mutations (e.g.,  BCL2 ), leading to a premalig-
nant tumor cell population (“CPC”) stable enough to ac-
quire further genetic events. This is followed by driver 
mutations in the progenitor clone (e.g.,  CREBBP ) that 
lead to an early malignant clone that may acquire further 
accelerator mutations (e.g.,  KMT2D and  TNFRSF14 ) 
during the pathway of disease progression  [53] .
 Intertumoral and Intratumoral Heterogeneity 
beyond Histopathological Classification: the 
Example of DLBCL 
 DLBCL, the most frequent B-NHL in adults, is clini-
cally heterogeneous in terms of treatment response and 
long-term outcome. The molecular basis of this heteroge-
neity was first characterized by Alizadeh et al.  [54] , who 
studied the cell-of-origin phenotype by DNA microar-
rays and identified distinct gene expression profiles re-
lated to germinal center B-cell (GCB) or activated B-cell 
types. A further layer of complexity was introduced by 
Lenz et al.  [55] , who identified signatures of the tumor 
microenvironment that are associated with survival. 
However, because these technologies are very costly and 
time consuming, they have not been implemented in the 
daily routine pathological diagnostics of DLBCL. Since 
the many DLBCL subtypes cannot readily be identified 
based on morphology alone, each case of suspected DLB-
CL requires a more or less extensive immunohistochem-
ical workup to be correctly classified for prognostic and 
predictive purposes. Hence, we use antibodies against 
CD20 and CD3 to establish the cell lineage (with CD20 
also being predictive for rituximab treatment); CD10, 
BCL6, MUM1, CD30, and CD5 to assess prognostic im-
munohistochemical cell-of-origin subgroups (GCB vs. 
non-GCB type; CD5 + type; and CD30 expression); and 
the expression of MYC and BCL2 proteins (double-
expressers with  ≥ 40% MYC- and  ≥ 50% BCL2-positive 
cells, respectively, that are associated with a worse prog-
nosis) and Ki-67 to address cell proliferation  [56] . The 
Hans classifier using CD10, BCL6, and MUM1 is the 
most widely used immunohistochemical surrogate mark-
er for the molecular cell-of-origin subgroups of GCB ver-
sus activated B-cell DLBCL types that was recently vali-
dated using NanoString ® technology  [54, 57, 58] . Other, 
less commonly used, classifiers include Visco-Young, 
Choi, Muris, Nyman, and Tally, some of which imple-
ment additional antibodies such as FOXP1, GCET1, 
BCL2, and LMO2  [56] . All classifiers have their advan-
tages and disadvantages and can complement each other 
in the classification of difficult cases. Intertumoral het-
erogeneity in DLBCL can thus readily be examined by 
pathologists and exemplifies a clinically important basis 
for prognosis and probably in the future also for treat-
ment decisions. Although subtyping of DLBCL according 
to the GCB versus non-GCB is recommended in the 2016 
updated version of the WHO classification  [15] , it is not 
yet clear which method or algorithm is the best to address 
this distinction for clinical purposes. Similarly, there is 
currently no accepted selection strategy to identify cases 
of high-grade B-cell lymphoma carrying translocations of 
 MYC with  BCL-2 and/or  BCL-6 , so-called double- or tri-
ple-hit lymphomas, which need to be recognized accord-
ing to the 2016 updated WHO classification  [15, 59] . 
Nevertheless, double- or triple-hit lymphomas are con-
centrated in the GCB type, whereas double-expressers are 
concentrated in the non-GCB group.
 In contrast to the long-recognized intertumoral het-
erogeneity in DLBCL, which is now implemented in dai-
ly diagnostics as outlined above, intratumoral heteroge-
neity in DLBCL is only beginning to be understood. A 
promising strategy to investigate DLBCL intratumoral 
heterogeneity is the genetic comparison of paired samples 
at first diagnosis and relapse. In doing so by deep se-
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quencing the variable, diversity, and joining regions of 
the immunoglobulin heavy chain in tumors from 14 re-
lapsed patients, Jiang et al.  [60] discovered 2 distinct evo-
lutionary scenarios of DLBCL. They could show that di-
agnosis and relapse tumors are clonally related, and char-
acterization of somatic hypermutation patterns allowed 
the identification of unique subclones. Phylogenetic anal-
ysis of these subclones revealed that the major subclone 
at diagnosis and relapse either had very different somatic 
hypermutation patterns (early divergence) or clustered 
together very closely (late divergence). The authors hy-
pothesized that in the early divergence mode of clonal 
evolution, diagnosis and relapse clones develop in paral-
lel, whereas in the late divergence mode relapse clones 
develop directly from the diagnosis clone. In addition, by 
targeted ultradeep resequencing and exome sequencing, 
they could demonstrate recurrent mutations in epigene-
tic modifiers such as  EP300 ,  KMT2D , and  SETDB1 in 
both diagnosis and relapse clones, as well as mutations in 
immune surveillance genes, such as  CD58 and  IL9R in 
relapse clones. This indicates that epigenetic modifiers 
are real driver mutations in DLBCL and that the failure 
of immune surveillance contributes to disease relapse 
 [60] . Similar conclusions were drawn by Juskevicius et al. 
 [61] , who also identified 3 clonally unrelated relapses in 
their cohort of 20 paired diagnosis-relapse samples.
 Mutations in epigenetic modifiers are frequent in
DLBCL  [62] ; however, the contribution of epigenomic al-
terations to tumor evolution is poorly understood. In an 
attempt to characterize the epigenome of DLBCL during 
disease progression, Pan et al.  [63] performed genome-
wide DNA methylation profiling in 13 diagnosis-relapse 
sample pairs at single base pair resolution. They found
heterogeneous evolution of DLBCL methylomes and iden-
tified a relapse-associated methylation signature enriched 
in key cellular pathways such as transforming growth 
factor-β signaling and antiapoptotic pathways. Important-
ly, the current standard treatment regimen for DLBCL (R-
CHOP; rituximab, cyclophosphamide, doxorubicin, vin-
cristine, and prednisolone) does not seem to be linked to 
direct effects on DNA methylation or epigenetic modifi-
ers, favoring the conclusion that epigenomic alterations 
are disease-intrinsic mechanisms of relapse  [63] .
 Transdifferentiation 
 In recent years, accumulating case reports have dem-
onstrated the cooccurrence of lymphoid and myeloid lin-
eage neoplasms with a clonal relationship. An example of 
transdifferentiation is shown in  Figure 4 . Reported cases 
include histiocytic/dendritic cell (H/DC) neoplasms in 
patients suffering from low-grade B-cell lymphomas, 
such as FL, Mantle cell lymphoma, hairy cell leukemia, or 
CLL/SLL  [64] , as well as Langerhans cell neoplasms in 
patients with lymphoblastic leukemia/lymphoma of ei-
ther B-cell (B-LBL)  [65] or T-cell (T-LBL)  [66] origin ( Ta-
ble 2 ). Myeloid differentiation in a low-grade lymphoma 
patient sample may pose diagnostic problems because of 
a morphologic resemblance to large cell lymphoma, mim-
icking transformation. In the cases reported in the litera-
ture, myeloid cell differentiation was suspected based on 
morphology (cells with abundant eosinophilic cytoplasm, 
spindle cells, and whorled growth pattern) but it was of-
ten confirmed after extensive an immunohistochemical 
workup using markers like CD34, CD43, CD33, CD68, 
CD163, lysozyme, S100, CD1a, and CD207. Therefore, 
though a very rare event, we suspect that the incidence of 
myeloid differentiation in lymphomas is likely underesti-
mated because of diagnostic difficulty and the lack of ap-
propriate immunohistochemical and molecular method-
ologies for its identification. Mechanistically, there are 
several models that may explain the cooccurrence of a 
lymphoid and a myeloid neoplasm in the same patient. 
Firstly, it could be a coincidence of 2 clonally unrelated 
neoplasms (de novo H/DC neoplasm). Secondly, both 
lymphoma and H/DC neoplasm could arise from an im-
mature CPC, because normal mature hematopoietic cells 
originate from multipotent hematopoietic stem cells that 
differentiate via oligopotent precursor cells along either 
the myeloid or the lymphoid lineages  [67] . Thirdly, plas-
ticity between lymphoid and myeloid cells could be ex-
plained by dedifferentiation of lymphoid cells towards 
more immature cell types, followed by differentiation 
along the myeloid lineage. And fourthly, lymphoid cells 
may directly transdifferentiate into myeloid cells. This 
latter hypothesis is supported by experimental models 
mainly used by Graf and colleagues, demonstrating that 
committed T-cell progenitors and B-cell lymphoma/
leukemia cells can be effectively transdifferentiated into 
myeloid cells by overexpression of  SPL1  ( PU.1 ) and/or 
 CEBPA transcription factors  [68–70] . In addition, Wang 
et al. [71, 72] found hypermutation in  IGVH loci in the 
H/DC neoplasm component in 2 patients harboring low-
grade lymphomas. This strongly suggests derivation from 
a mature B cell that underwent somatic hypermutation in 
the LN germinal center reaction  [71, 72] . A seminal study 
by Feldman et al. [73] investigated 8 patients with FL and 
syn- or metachronous H/DC neoplasm, a clonal relation 
which was proven by demonstration of identical t(14; 18) 
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translocations and  IGH rearrangements in both FL and 
H/DC clones. They postulated that the H/DC tumor aris-
es from either a differentiated FL cell or a CPC at least at 
the pre-B-cell stage of differentiation. In contrast, Buser 
et al.  [74] , who analyzed a compound pro-T LBL and in-
determinate dendritic cell tumor simultaneously occur-
ring at 3 different anatomical sites in a 59-year-old wom-
an, found a tri(21) in both tumor components, whereas 
only the pro-T LBL additionally contained a monoso-
my(18) and  NRAS G13D mutation. Therefore, they con-
cluded that this composite tumor must have arisen by di-
vergent cell differentiation from a CPC  [74] . Zhang et al. 
 [75] reported on a very unusual case of biphasic FL pro-
gression presenting as a collision tumor consisting of an 
H/DC sarcoma along with DLBCL in the hip of a 50-year-
old male who harbored an FL in the axillary LN. In this 
intriguing example of spatial and intratumoral heteroge-
neity, the authors could show that all 3 different tumors 
were clonally related by analysis for  BCL2 rearrangement, 
and they concluded that both DLBCL and H/DC sarcoma 
had arisen from the FL clone  [75] . On the other hand, 
Brunner et al.  [76] provided elegant evidence for a CPC 
giving rise to FL and histiocytic sarcoma using fluores-
cence in situ hybridization (FISH) and array comparative 
genomic hybridization studies. In their case report, the 
histiocytic sarcoma clone contained a t(14; 18) transloca-
a b c
d e f
g h i
 Fig. 4. Example of transdifferentiation of chronic lymphocytic leu-
kemia/small lymphocytic lymphoma (CLL/SLL) to Langerhans 
cell histiocytosis (LCH).  a Bone marrow (BM) infiltration by small, 
round lymphocytes with little cytoplasm and dense nuclear chro-
matin, corresponding to CLL/SLL (Giemsa stain). Immunohisto-
chemically, the CLL/SLL cells are weakly positive for CD20 ( b ) and 
strongly positive for CD5 ( c ), and they show intermediate positiv-
ity for CD23 ( d ) and positivity for PAX5 ( e ). In the femur of the 
same patient, radiological imaging revealed a mass that was suspi-
cious for high-grade transformation.  f An excisional biopsy was 
performed, which showed large polygonal cells with histiocytic 
morphology, abundant eosinophilic cytoplasm, and bean-shaped 
nuclei. These cells were positive for S-100 ( g ) as well as CD1a (not 
depicted) and negative for PAX5 ( h ).  i Staining with an antibody 
specific for the  BRAF V600E mutation was positive. Molecular 
analyses revealed identical  IGH rearrangements and  TP53 muta-
tions in both the CLL/SLL and the LCH tumors. The LCH compo-
nent exhibited an additional  BRAF V600E mutation, which was 
absent in the CLL/SLL component. 
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tion and clonal  IGH rearrangement identical to the FL 
clone; however, the FL clone had additional complex
genetic changes detected by array comparative genomic 
hybridization that were not present in the histiocytic
sarcoma, ultimately favoring the CPC hypothesis  [76] .
 In summary, experimental and clinical evidence indi-
cates that different mechanisms may lead to H/DC neo-
plasms in patients suffering from lymphomas, the most 
frequent one being transdifferentiation from mature tu-
mor lymphocytes ( Table 2 ). For future studies that inves-
tigate transdifferentiation, it is essential to properly ad-
dress this issue using molecular techniques, either by 
physically separating the 2 tumor types via immune-di-
rected laser capture microdissection or by morphology-
directed FISH for chromosomal aberrations  [64] .
 Clinical and Radiological Implications of Tumor 
Heterogeneity in Lymphomas 
 The morphologic, immunophenotypic, and molecular 
heterogeneity of lymphomas has a major influence on 
clinical practice and therapy decisions at different time 
points in the course of the disease. At first diagnosis, it is 
 Table 2.  Examples of transdifferentiation
Cases,
n
Postulated cell 
of origin
Lymphoid 
neoplasm
Myeloid neoplasm Clonal relationship Reference
1 CPC B-LBL Langerhans cell sarcoma Identical IGH and TCRG rearrangement 65
2 CPC T-LBL Langerhans cell sarcoma Identical TCRG rearrangement 66
8 Mature tumor cell
or CPC
FL Histiocytic sarcoma (n = 7), 
interdigitating DC sarcoma 
(n = 1)
Identical BCL2 and IGH rearrangement 73
1 CPC T-LBL Indeterminate DC tumor tri(21) 74
1 Mature tumor cell 
or CPC
FL (axilla) 
DLBCL (hip)
H/DC sarcoma (hip) Identical BCL2 rearrangement 75
2 Mature tumor cell FL (n = 1)
DLBCL (n = 1)
H/DC sarcoma Identical IGH rearrangement 102
1 Mature tumor cell FL H/DC sarcoma Identical BCL2 and IGH rearrangement 103
2 Mature tumor cell Splenic MZL 
(n = 1)
FL (n = 1)
Histiocytic sarcoma Identical IGH rearrangement 71
1 Mature tumor cell CLL/SLL Interdigitating DC sarcoma Identical IGH rearrangement
tri(12)
104
7 Mature tumor cell CLL/SLL Interdigitating DC sarcoma 
(n = 4)
Langerhans cell sarcoma (n = 1)
Histiocytic sarcoma (n = 2)
Identical IGH rearrangement 105
2 Mature tumor cell FL Langerhans cell neoplasm Identical BCL2 and IGH rearrangement 106
1 Mature tumor cell 
or CPC
Nodal MZL Langerhans cell sarcoma Identical IGH rearrangement
del(11q), tri(12)
107
1 Mature tumor cell CLL/SLL Langerhans cell sarcoma del(6q23) 108
2 NA FL (n = 1)
FL, DLBCL 
(n = 1)
Histiocytic sarcoma Identical BCL2 rearrangement 109
1 CPC FL Histiocytic sarcoma Identical BCL2 and IGH rearrangement 76
1 Mature tumor cell MCL Histiocytic sarcoma Identical IGH rearrangement and 
CCND1-IGH fusion
110
1 CPC HCL Histiocytic sarcoma BRAF V600E
Multiple cytogenetic aberrations (aCGH)
111
CPC, common progenitor cell/clone; NA, not applicable; B-LBL, B-cell lymphoblastic leukemia; T-LBL, T-cell lymphoblastic leuke-
mia; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; MZL, marginal zone lymphoma; CLL/SLL, chronic lymphocytic 
leukemia/small lymphocytic lymphoma; MCL, Mantle cell lymphoma; HCL, hairy cell leukemia; DC, dendritic cell; H, histocytic.
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important to classify the lymphoma correctly because the 
best therapy for an individual patient can vary from 
“watch and wait” to multimodal (radio-, immuno-, and 
chemo-) therapy, depending on variables such as disease 
subtype, evidence for high-grade transformation, and 
various molecular risk factors  [16–19] .
 As described above, disease heterogeneity may present 
as transformation from low- to high-grade lymphoma or 
as a second, clonally unrelated neoplasm. Clinical suspi-
cion for transformation is based on rising serum lactate 
dehydrogenase levels, rapidly progressive lymphadenopa-
thy, unexplained deterioration of the general condition, 
the appearance of B symptoms, or the development of ex-
tranodal disease  [77] . Due to its prognostic relevance and 
impact on therapy decisions, high-grade transformation 
of low-grade B-NHL needs to be confirmed by a biopsy, 
since it can be mimicked by a variety of unrelated condi-
tions. Because transformation can arise focally, selection 
of the best location for biopsy based on clinical findings 
and imaging studies is critical. In this context,  18 F-fluoro-
deoxyglucose positron emission tomography/computed 
tomography ( 18 F-FDG-PET/CT), which is routinely per-
formed for clinical staging or reevaluation of lymphoma 
patients, can provide additional help  [78, 79] . High stan-
dardized uptake values in  18 F-FDG-PET/CT correlate with 
high-grade histology and show a positive predictive value 
for transformed lymphoma. Therefore, high standardized 
uptake values in  18 F-FDG-PET/CT may guide the best site 
for biopsy  [80–82] . In patients who cannot undergo inva-
sive diagnostic procedures due to impaired coagulation, 
 18 F-FDG-PET/CT may corroborate a suspicion for relapse 
or high-grade transformation but does clearly not carry 
the same diagnostic weight as a tissue biopsy.
 Another indication for a repeat biopsy is to demon-
strate a potential change in the surface marker profile. As 
discussed above, the administration of rituximab can lead 
to a loss of CD20 expression on the neoplastic cells and/
or to increased plasma cell differentiation, which may re-
quire a modification of therapy.
 The survival of patients with high-grade transforma-
tion of a preexisting low-grade HNL is generally worse as 
compared to patients with de novo high-grade disease, 
with a slight improvement in the era of rituximab. This 
inferior outcome is the result of both patient-specific and 
tumor-related factors, such as previous therapies, delayed 
hematopoietic recovery, and lower response rates after 
therapy on one hand and a more frequent presence of 
molecular risk factors and preselection of resistant clones 
on the other  [82] . Patients with composite or transformed 
lymphomas are often excluded from clinical trials, and 
since standard therapies are lacking, current therapy con-
cepts are highly individualized, with autologous or allo-
geneic hematopoietic stem cell transplantation as poten-
tial options in fit patients  [33] .
 The current rapid advances in molecular diagnostics 
with the identification of novel genetic and epigenetic al-
terations, as well as an improved characterization of the 
tumor microenvironment have led to new insights into 
the pathogenesis of lymphoma and provide an opportu-
nity for refined, biology-based treatments. However, the 
validation and integration of novel biomarkers in daily 
clinical practice and their translation into new treatment 
algorithms remains a challenge  [83] . CLL/SLL is a pa-
radigmatic disease in which molecular heterogeneity
directly influences treatment decisions. In CLL/SLL, 
del(17p) is associated with a worse prognosis and a resis-
tance against fludarabine and alkylating agents. Muta-
tions of the  TP53 gene and an unmutated  IGHV status
are also associated with an adverse outcome, and these 
molecular alterations favor treatment decision towards 
high-intensity therapy with the use of novel agents like 
inhibitors of the B-cell antigen receptor signaling path-
way such as ibrutinib or allogeneic hematopoietic stem 
cell transplantation in fit patients  [84, 85] .
 Concluding Remarks 
 Personalized therapy for lymphoma patients requires 
precision diagnostics on all levels from molecular studies 
to radiological imaging. The current diagnostic gold stan-
dard still is histopathology; however, novel molecular de-
velopments will likely guide treatment decisions in the 
near future. The studies discussed in this review have pro-
vided important and invaluable insights into the genetic 
heterogeneity and pathogenesis of lymphomas, but 
knowledge about the genotypes in tumor cell clones at the 
single-cell level is still lacking. In addition, besides single-
cell genome, epigenome, and transcriptome information, 
future investigations should include single-cell pro-
teomes and metabolomes  [86–94] and address the cells of 
the tumor microenvironment, like immune cell subsets. 
In addition, methods to analyze these parameters in situ 
in intact tissue will become crucial to investigate cellular 
localization and cell-cell interactions  [95–99] . Computa-
tional integration of all these data in a so-called “cancer 
phenomics” approach will possibly guide future person-
alized medicine  [100, 101] . In conclusion, tumor hetero-
geneity in lymphomas will keep scientists, clinicians, and 
pathologists busy for time to come.
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